Business
Alzamend Neuro Partners with QMENTA, to Advance AI-Powered Imaging for its Phase II Clinical Trial of AL001 Study to Take Place at Massachusetts General Hospital
Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA, May 07, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stre
About this update from Alzamend Neuro, Inc.
[{"type":"image","alt":"Alzamend Neuro, Inc.","displaySize":"","headline":null,"caption":"Alzamend Neuro, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":71,"url":"https://media.zenfs.com/en/globenewswire.com/beaa4f3451e46424f3f01617d10e3695"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_uEJOJXjxPyeOYcOwc1Xqg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk5O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/beaa4f3451e46424f3f01617d10e3695","width":300,"height":71}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects","length":187,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":187,"olType":false},{"type":"text","content":"ATLANTA, May 07, 2025 (GLOBE NEWSWIRE) -- Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced its partnership with Mint Labs Inc. d/b/a QMENTA (“QMENTA”), a leading medical imaging artificial intelligence (“AI”) company, to support its five upcoming Phase II clinical trials of AL001 at Massachusetts General Hospital.","length":574,"tagName":"p"},{"type":"image","alt":"QMENTA Corporate Logo","displaySize":"","headline":null,"caption":"QMENTA Corporate Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":1048,"height":281,"url":"https://media.zenfs.com/en/globenewswire.com/ecbb983c5a98e0af57eeffea62801e1c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/052zZjkPFJ4Mp.0kEkuxQA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI1NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ecbb983c5a98e0af57eeffea62801e1c","width":960,"height":257},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/aAOHQZhBwQSZxVcMXSJ0Hw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwOTY7aD01NjI7Y2Y9d2VicA--/https://media.zenfs.com/en/globenewswire.com/ecbb983c5a98e0af57eeffea62801e1c","width":1048,"height":281}}},{"type":"text","content":"QMENTA’s cloud-based platform will manage and analyze medical imaging data throughout the trials, ensuring re...